You can restrict your search to only Treatment Centers or only Clinical Trials by checking the Treatment Center or Clinical Trial checkbox under TYPE. Use the Zoom-In (+ sign on the lower right of the map) to enlarge the map area to find your preferred location. To search for a Treatment Center or Clinical Trial, click on the red map pin for the name of the facility. Click on the name of the facility for more details.
Brief Summary:
This phase II trial studies how well pembrolizumab works in treating patients with stage IB-IV mycosis fungoides. Antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread.
Website: https://clinicaltrials.gov/ct2/show/NCT03695471?term=mc1788&draw=2&rank=1
PRIMARY OBJECTIVE:
Brief Summary
The purpose of this study is to test any good and bad effects of the study drug called brentuximab vedotin at a lower dose than is FDA-approved.
Website: https://clinicaltrials.gov/study/NCT03587844
Sponsors: Memorial Sloan Kettering Cancer Center
Contacts and Locations
Brief Summary:
Brief Summary
The purpose of this research study is to evaluate the effectiveness and safety of Ritlecitinib in skin and blood in persons with Cutaneous T-Cell Lymphoma (CTCL). CTCL is a rare type of cancer that starts in the white blood cells and eventually can result in rashes or tumors in the skin. This study includes a 24 week Treatment Period and a 24 week Follow-up Period. This study will involve physical examinations, visual assessments, laboratory tests, PET-CT scans, electrocardiograms, photographs of your skin, skin biopsies, and hearing tests.
Description
Brief Summary
The purpose of this study is to find out whether the combination of pembrolizumab and gemcitabine is an effective treatment for mycosis fungoides and Sézary syndrome.
Website: https://clinicaltrials.gov/study/NCT04960618#contacts-and-locations
Sponsors: Memorial Sloan Kettering Cancer Center
Contacts and Locations
Brief Summary:
Brief Summary
The goal of this clinical trial is to assess the benefit of continuous treatment with synthetic hypericin ointment (HyBryte) and visible light in patients with mycosis fungoides for up to 12 months (54 weeks). Funding Source: FDA OOPD.
Website: https://www.clinicaltrials.gov/study/NCT05872854
Sponsor: Ellen Kim, MD
Detailed Description
Brief Summary
Brief Summary:
Brief Summary
This study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma
Website: https://clinicaltrials.gov/study/NCT05079282
Sponsors and Collaborators: Ono Pharmaceutical Co. Ltd
Contacts and Locations
Brief Summary
This is a prospective, observational, non-interventional, international, multi-center, mixed methods study that will involve the integration of quantitative and qualitative data in patients with MF/SS treated with Poteligeo.
Website: https://clinicaltrials.gov/study/NCT05455931?term=PROSPER&cond=Cutaneous%20Lymphomas&rank=1
Brief Summary:
This is a Phase 1/1b, open-label, first in human study of CPI-818, an oral interleukin-2-inducible tyrosine kinase (ITK) inhibitor for the treatment of relapsed/refractory (R/R) T-cell lymphoma.. This trial will study the safety, tolerability, and anti-tumor activity of CPI-818 as a single drug. This trial is composed of dose escalation and dose expansion cohorts.
Brief Summary
This study will test the safety of ruxolitinib, given at one dose that does not change, and duvelisib, given at different doses, to find out what effects, if any, the study treatment has on people with relapsed or refractory NK-cell or T-cell lymphoma.
Website: https://clinicaltrials.gov/study/NCT05010005
Sponsor: Memorial Sloan Kettering Cancer Center
Eligibility Criteria
Permitted histologies include:
Brief Summary:
This is an international, multicenter, multi-arm, phase Ib, model-based dose-escalation study. The primary objectives of the study in each arm is to determine the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), dose limiting toxicities (DLTs) and to evaluate the clinical efficacy at the MTD of various combinations of pembrolizumab, pralatrexate and decitabine.
